In addition to mTORC1 inhibitors, our analysis also identified additional classes of drugs, as well as specific drugs, capable of reverting the LAM signature, such as antiproliferative CDK inhibitors, and MEK/MAPK inhibitors, which might induce cytotoxicity against the LAM cells. Here, MAP2K7 is linked to lymphangioleiomyomatosis.